Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Gulf Resources, Inc. received a formal notification from Nasdaq stating that the company has regained compliance with periodic filing requirements under Listing Rule 5250(c)(1). The company had previously been in violation of continued listing standards, but the Staff has now determined the matter is closed.
Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.
Curaleaf Holdings, Inc. has filed a Notice of Variation to its existing tender offer to acquire all outstanding shares of Aurora Cannabis Inc. The amended offer increases the consideration to US$1.00 in cash plus 0.4013 Curaleaf subordinate voting shares per Aurora share and extends the expiry date to December 4, 2026.
Powercompute Wins Contract from Columbus Light and Water
PowerCompute's subsidiary entered into a new Industrial Power Contract with Columbus Light and Water to increase contracted power at its Mississippi data center from 8.5 MW to 11 MW. The agreement transitions the facility to a specific Large Data Service Rate, successfully avoiding approximately $1.5 million per megawatt in new capacity commitment charges imposed by the Tennessee Valley Authority. Additionally, the utility returned a $300,000 cash deposit to the company, which will be replaced by a utility bond.
Microbot Medical Wins Contract from Medtechnica Ltd.
Microbot Medical Inc. entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY Endovascular Robotic System in Israel. The company expects initial orders under the agreement to begin in the fourth quarter of 2026 following prior regulatory approval from the Israeli Ministry of Health.
Auddia Inc. cancelled its special stockholder meeting intended to vote on its proposed merger with Thramann Holdings because it failed to secure approval from a majority of outstanding shares, despite 89% of cast votes being in favor. The company plans to establish a new record date and reschedule the meeting to allow shareholders to evaluate recent strategic momentum regarding LT350's AI infrastructure platform. The merger, originally announced in February 2026, would form a new AI-native operating company called McCarthy Finney.
Option Care Health Signs $5.8B M&A Deal with Investor Group
Option Care Health has entered into a definitive agreement to be acquired by an investor group led by Clayton, Dubilier & Rice (CD&R) and McKesson Corporation for $32.05 per share in cash. The transaction reflects a total enterprise value of approximately $5.8 billion and will result in Option Care Health becoming a privately held company with CD&R as the majority owner.
ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review. While the drug showed clinical benefit in secondary endpoints and a consistent safety profile, it failed to show a statistically significant improvement over chemotherapy. The company is currently evaluating the full dataset to determine the future development path for the candidate.
PDS Biotechnology announced it will host a virtual Key Opinion Leader (KOL) event on October 15, 2026, to discuss clinical outcomes from the PDS0301 Phase 2 trials. The event will focus on the metastatic colorectal cancer (mCRC) cohort, specifically patients with unresectable microsatellite stable (MSS) liver metastases, a population where immunotherapy has historically been ineffective.
Netlist Licensing Deal with Micron Technology, Inc Worth $600M
Netlist entered into a five-year patent license and settlement agreement with Micron Technology, resolving all pending legal proceedings between the companies. Micron will pay Netlist $30 million per quarter through Q3 2031, totaling $600 million, and will also purchase 10 million shares of Netlist common stock for $1 million.
Mckesson Signs $5.8B M&A Deal with Option Care Health, Inc.
McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health for $32.05 per share, representing a total enterprise value of approximately $5.8 billion. Upon closing, CD&R will hold a majority stake while McKesson will hold a minority interest in the home and alternate site infusion services provider. The deal aligns with McKesson's strategy to expand access to innovative therapies in lower-cost community and home settings.
Telomir Pharmaceuticals raised approximately $5.6 million in a PIPE financing through the issuance of 4,843,300 shares of common stock at $1.16 per share. The offering included a $1.0 million investment from existing shareholder John Paul DeJoria and will be used to fund the clinical development of Telomir-Zn for triple-negative breast cancer.
Value
$5.6M
Counterparty
John Paul DeJoria
“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir. Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”
John Paul DeJoria
“We have been very deliberate about how and when we access the capital markets. Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”
Boost Run Inc.'s subsidiary entered into a material service agreement with Cohere Inc to provide dedicated GPU cloud computing infrastructure and related services. Cohere has committed to pay approximately $525.6 million over a five-year term, with infrastructure delivery expected to begin in the second quarter of 2027.
Evolution Metals & Technologies Partnership with INERGX Energy Optimisation Ltd.
Evolution Metals & Technologies Corp. (EM&T) entered into a Strategic Partnership Letter of Intent with UK-based INERGX to engineer and service energy storage systems for EM&T's planned critical materials facility in the U.S. The partnership includes a non-China supply mandate for battery components and a 10-year anticipated service term. The facility is planned to reach up to 5 GW of on-site capacity at full build-out, powered by on-site LNG generation.
OFS Capital Divestiture to New Investor for $52.3M
OFS Capital Corporation's subsidiary, SBIC I LP, admitted a third-party investor who acquired a 56.62% limited partnership interest for $52.3 million. SBIC I LP holds a significant stake in Pfanstiehl Holdings, Inc., and the proceeds will be used by the company to fund new investments and for general corporate purposes.
Regeneron Pharmaceuticals Research Collaboration with Sanofi Worth $1B
Regeneron and Sanofi entered into a Sixth Amendment to their existing Antibody LCA to co-develop and co-commercialize four new long-acting antibodies targeting IL-13, IL-4, and IL-4Rα. Sanofi will pay Regeneron an upfront payment of $1.0 billion and up to $7.0 billion in potential development, regulatory, and commercial milestones, with global profits and development costs shared equally.
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.
Professional Diversity Network Capacity Expansion: $1.18M Investment
Professional Diversity Network's subsidiary, PDN Intelligence, committed $1.177 million to acquire and finance two NVIDIA B300 GPU systems, marking its initial entry into AI computing infrastructure. The company is leasing one system to Goodwill Labs and providing a secured loan for a second system, with operations supported by technical partner HashForest. This move represents a strategic shift from planning to execution in the company's AI infrastructure business.
Value
$1.18M
Counterparty
Goodwill Labs Inc.
Term
60 months
“We are moving from strategy to execution. By placing our initial order and committing capital toward next-generation AI computing infrastructure, we are establishing the foundation for PDN Intelligence’s operations.”
Yiran Gu, Chief Executive Officer and Chief Financial Officer
“We believe demand for advanced computing capacity will continue to create opportunities across the AI ecosystem. Our approach is to begin with disciplined infrastructure deployment, establish operating capabilities and evaluate future expansion based on market demand, utilization and economics.”
Yiran Gu, Chief Executive Officer and Chief Financial Officer
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. provided a status update on its pending merger with Supernus Pharmaceuticals, Inc., specifically addressing supplemental disclosures to the joint proxy statement/prospectus. The update follows demand letters and complaints from Supernus stockholders alleging disclosure deficiencies, which the company believes are meritless but is addressing to avoid litigation risk. The special meetings for stockholders of both companies to vote on the merger are scheduled for October 15, 2026.
Barnwell Industries Divestiture to 2798913 Alberta Ltd.
Barnwell Industries has entered into a definitive agreement to sell its Canadian oil and natural gas business to 2798913 Alberta Ltd. for a base purchase price of C$9,000,000. The consideration includes C$4,000,000 in cash and a 5% gross overriding royalty on future wells (valued at C$5,000,000), which the buyer has an option to buy out for an additional C$5,000,000.
HighPeak Energy entered into agreements to raise $450 million through the private placement of 450,000 shares of newly created Series A 6.0% Perpetual Convertible Preferred Stock to subsidiaries of PT Danantara Investment Management and PT Energi Mega Persada Tbk. The proceeds, combined with a new $800 million reserve-based credit facility, will be used to refinance and repay the company's existing $1.17 billion term loan in full.
Value
$450M
Counterparty
PT Danantara Energy International and PT Tunas Harapan Perkasa
“Today marks a milestone for HighPeak Energy. This comprehensive refinancing will materially strengthen our balance sheet, significantly reduce our financing burden and enhance our ability to generate long-term value for shareholders. The combination of permanent capital from high-quality investors alongside a new reserve-based lending facility will enable HighPeak to retire its existing term loan and establish a much more effective capital structure.”
Michael Hollis, President and Chief Executive Officer
“We expect that this transaction will improve our liquidity profile, materially reduce our annual interest expense, and provide us with greater financial flexibility to focus on disciplined development, free cash flow generation and continued shareholder value creation.”
Michael Hollis, President and Chief Executive Officer
Artificial Intelligence Technology Solutions Wins Contract from Global Logistics Client
AITX's subsidiary, Robotic Assistance Devices (RAD), has secured an order for a third ROAMEO autonomous security patrol vehicle from a global logistics client. The vehicle will be deployed at a cosmetics manufacturer's site to replace or augment manned security patrols, with delivery expected by the end of 2026.
Adia Med Divestiture to Live Oak Health LLC for $1.5M
Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell a 30% interest in its subsidiary, Adia Labs LLC, to Live Oak Health LLC (dba QCM Biologics) for $1.5 million. The consideration consists of $1.0 million in cash and a $0.5 million promissory note, with the buyer also receiving an option to purchase an additional 10% stake for $0.5 million. Despite the minority equity sale, the agreement establishes equal 50/50 voting power between Adia Med and the buyer regarding member matters.
Reliance Global Group completed the sale of its Altruis Benefit Consulting subsidiary for $8 million in cash plus a potential $1 million earnout. The transaction is part of the company's portfolio monetization strategy to divest non-core assets and redeploy capital into its proprietary AI platform and RELI Exchange network.
Firy Inc. completed the sale of its entire 10.5% equity stake in Hamburg-based developer Exit Games GmbH back to the counterparty for $55 million in cash. The transaction represents a fully realized cash exit from a 2021 investment, providing the company with increased balance sheet liquidity and optionality.
Novagold Resources M&A Deal with Paulson Advisers LLC
NOVAGOLD has filed and commenced mailing proxy materials for a special meeting on November 3, 2026, to approve the acquisition of the remaining 40% interest in Donlin Gold LLC from Paulson Advisers LLC. The all-share transaction will increase NOVAGOLD's ownership of the Donlin Gold project in Alaska from 60% to 100% and involve a re-domestication to Delaware.
UWM Holdings Corporation has commenced a $400 million rights offering, allowing existing Class A stockholders to purchase shares at a subscription price of at least $2.00 per share. The offering is supported by a backstop agreement from CEO Mat Ishbia and Oaktree Capital Management, ensuring the company raises the full $400 million regardless of shareholder participation. Proceeds will be used for general corporate purposes, with the rights offering set to expire on November 12, 2026.
Aviat Networks Licensing Deal with Dixon Electro Appliances Private Ltd.
Aviat Networks, through its subsidiary, entered into an intellectual property license agreement with Dixon Electro Appliances Private Ltd. (DEAPL) to manufacture and sell WTM 4000 microwave radios in India. The partnership allows Aviat to address the 'Made in India' market requirements while retaining its IP and providing software and services, targeting an estimated demand of 250,000 links over the next four years.
Equillium received clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme to initiate a Phase 1 clinical trial of EQ504. The study will evaluate the safety and pharmacokinetics of the oral drug in healthy participants, with dosing expected to begin in early November 2026.
Apollo IG Core Replacement, L.P. issued unregistered limited partnership interests for approximately $3.0 million in cash on October 1, 2026. The sale was conducted as part of the fund's continuous private offering. Additionally, the company reported a net asset value (NAV) of $1,317.2 million as of August 31, 2026.
Fathom Holdings M&A Deal with Neighborhood Intelligence, Inc.
Fathom Holdings and Neighborhood Intelligence (formerly Bed Bath & Beyond) have mutually agreed to terminate their previously announced merger agreement, citing that current market valuations do not reflect the fair value of either company. No termination fees will be owed by either party, and the companies intend to explore future strategic collaborations such as data sharing. Additionally, Fathom extended the maturity date of its senior secured convertible promissory notes to November 1, 2026, and lowered the conversion price to $0.65 per share.